2020 SEP 29 Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients

GOOGLE A Serious Violators of the 1st Amendment

FACEBOOK A Serious Violators of the 1st Amendment

YOUTUBE A Serious Violators of the 1st Amendment

TWITTER A Serious Violators of the 1st Amendment

Remarks: The Study Highlights: Early treatment with HCQ on the first day of admission is associated with a reduced risk of 53% in transfer to the ICU for mechanical ventilation. FULL STORY HERE: https://www.4cmitv.com/2020/09/30/2020-sep-29-early-hydroxychloroquine-but-not-chloroquine-use-reduces-icu-admission-in-covid-19-patients/

The Fourcm (4cm) Group: 4cminewswire.com 4cmitv.com 4cminews.com fourcm.net

4cm Social Media: PARLER @Gary4cm GAB @4cminewsire TWITTER: @4cmtvworld TWITTER: @4cminews YOUTUBE: @GaryGreen4CMiCTV BITCHUTE: @Freedom4CM

CRAIG KELLY MP HEADLINES: And Another One (Study) Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients

In the future, studies will find that those that continued to deny (in light of the overwhelming evidence) that HCQ could have been effective had become infected by a form of mental illness – and further those that continued to TO DENY OTHERS ACCESS to this medicine (that the observational evidence shows is saving lives) had engaged in crimes against humanity.

And a memo to the National Evidence COVID Taskforce who are currently fumbling around in the dark, trying to figure out how to backtrack from their previous mistaken recommendations – just ‘lance the boil’ and state ‘’in the light of new evidence’’ you have changed your mind.

“Observational study 1064 hospitalized patients in the Netherlands, 53% reduced risk of transfer to the ICU for mechanical ventilation with HCQ treatment starting on the first day of admission.”

And we are only left to speculate how much more effective the treatment would have been if was combined with Zinc + AZ, and treatment has started immediately upon the first sign of symptoms (prescribed by a family doctor) rather than delayed until they reached hospital.

ORIGINAL SOURCE: Date-stamped:2020 Sep 29 | Author: Craig Kelly MP | Post Title: And Another One {Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients} Post Link: @CraigKellyMP

See: https://c19study.com/lammers.html (Lammers et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2020.09.1460 (Peer Reviewed).)

FULL COPY OF PUBLISHED STUDY

Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients

IJID online: https://www.ijidonline.com/article/S1201-9712(20)32175-5/fulltext

Published: September 29, 2020

DOI: https://doi.org/10.1016/j.ijid.2020.09.1460

Abbreviations: HCQ (hydroxychloroquine), CQ (chloroquine), AZM (azithromycin), ICU (intensive care unit), ED (emergency department)

Authors: A.J.J. Lammers, R.M. Brohet, R.E.P. Theunissen, H. Bax, D.F. Postma, P.H.P. Groeneveld

ABSTRACT

BACKGROUND

The global push for the use of hydroxychloroquine (HCQ) and chloroquine (CQ) against COVID-19 resulted in an ongoing discussion about the effectivity and toxicity of these drugs. Recent studies report no effect of (H)CQ on 28 day-mortality. We investigated the effect of HCQ and CQ in hospitalized patients on the non-ICU COVID-ward.

METHODS

A nationwide, observational cohort study was performed in The Netherlands. Hospitals were given the opportunity to decide independently on the use of three different COVID-19 treatment strategies: HCQ or CQ, or no treatment. We compared the outcome between these groups. The primary outcomes were 1) death on the COVID-19 ward, and 2) transfer to the Intensive Care Unit (ICU).

RESULTS

The analysis contained 1064 patients from 14 hospitals: 566 patients received treatment with either HCQ (n = 189) or CQ (n = 377), and 498 patients received no treatment. In a multivariate propensity matched weighted competing regression analysis, there was no significant effect of (H)CQ on mortality on the COVID-ward. HCQ however was associated with a significant decreased risk of transfer to the ICU (Hazard ratio (HR) = 0.47, 95%CI = 0.27–0.82, p = 0.008), when compared to controls. This effect was not found in the CQ group (HR = 0.80; 95%CI = 0.55–1.15, p = 0.207), and remained significant after competing risk analysis.

CONCLUSION

The results of this observational study demonstrate a lack of effect of (H)CQ on non-ICU mortality.

However, we show that the use of HCQ – but not CQ – is associated with 53% decreased risk of transfer of COVID-19 patients from the regular ward to the ICU.

Recent prospective studies have reported on 28 days all-cause mortality only, therefore additional prospective data on the early effect of HCQ in preventing transfer to the ICU is still needed.

FILE SIZE: 3 mb

PAGES: 33

DOWNLOAD PDF:

ijidonline-PIIS1201971220321755

Hashtags: #4cminewswire, #HCQ, #Hydroxychloroquine, #AZM, #Azithromycin, #COVID19, #4cminews, #4CMiTV, #4CM2020SEP29,

Tags: 4cminewswire, HCQ, Hydroxychloroquine, AZM, Azithromycin, COVID-19, 4cminews, 4CMiTV, #4CM2020SEP29,

4CMINEWS SOCIAL MEDIA: